New research suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a major health publication shows that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these medications need to be informed of the potential of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass within about 18 months.
Weighing Treatments
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone usually see a slower creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Experts propose the mode of action of the jabs is key to understanding the accelerated regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, considering the high risk of relapse, the treatment should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic character of obesity," akin to managing diseases like diabetes.
User Accounts
Users who have discontinued the medication describe a intense return of appetite.
"It was like a switch activating and you become extremely hungry," said one woman.
The struggle is exacerbated if patients have not developed permanent dietary or behavioural changes during treatment.
Growing Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and long-term success hinges on ongoing behavioural management.
